In patients with concomitant aortic and mitral valve disease is aortic valve replacement with mitral valve repair superior to double valve replacement?
Language English Country Great Britain, England Media print-electronic
Document type Comparative Study, Journal Article, Review
PubMed
21081554
DOI
10.1510/icvts.2010.251876
PII: icvts.2010.251876
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Cardiac Valve Annuloplasty adverse effects methods MeSH
- Aortic Valve physiopathology surgery MeSH
- Heart Valve Prosthesis Implantation adverse effects methods MeSH
- Risk Assessment MeSH
- Humans MeSH
- Evidence-Based Medicine MeSH
- Mitral Valve physiopathology surgery MeSH
- Follow-Up Studies MeSH
- Heart Valve Diseases complications diagnosis mortality surgery MeSH
- Sensitivity and Specificity MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Comparative Study MeSH
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: in patients with concomitant aortic and mitral valve disease is aortic valve replacement with mitral valve plasty (MVP) superior to double valve replacement (DVR) in terms of improved long-term survival? Altogether 156 papers were found using the reported search, of which seven represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Out of seven papers, that simultaneously compare these two treatment modalities, three favor MVP combined with aortic valve replacement (AVR) over DVR, two papers advocate the opposite and two failed to find any significant difference in long-term survival, freedom from reoperation and thromboembolic and bleeding complications between these two surgical options. All data presented derive from level 2b evidence. Critical appraisal of these studies is constricted by the large heterogeneity of the patients, diversity in treatment protocols and inherent selection bias. We conclude that currently the available evidence is insufficient to prove that AVR with MVP is superior to DVR in patients with double valve disease.
References provided by Crossref.org